Nintx
Felipe Lemos is a seasoned financial professional with extensive experience in financial and administrative management. Currently serving as the Financial and Administrative Manager at Nintx since September 2022, Felipe previously held the position of Head Financeiro e Administrativo at Tuddu and co-founded FERFI Consultoria em Benefícios e Corretora de Seguros, where significant achievements included the management of R$ 80 million in premiums and spearheading a successful Due Diligence process during a corporate acquisition. Felipe also has experience as a Financial Analyst at Marítima Seguros, where responsibilities included managing cash flow and improving accounts receivable processes. An educational background includes an MBA in Finance from Insper and ongoing studies in Accounting at FACULDADE FIPECAFI.
This person is not in any teams
Nintx
Originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants and microorganisms) into novel therapies, Nintx (Next Innovative Therapeutics) believes plant-based natural products bear huge potential to serve as a superb platform to modulate human biological targets and the microbiome concomitantly, affording therapies for multifactorial diseases (multi-target therapies). Nintx was founded by two experienced PhD scientists, Dr. Miller Freitas (CEO) and Dr. Cristiano Guimarães (CSO), who are the main executives of the company, and Mr. Stephani Saverio, MBA, a healthcare veteran who has been acting as a Non-Executive Board Member for the startup. Nintx is a startup with innovation as core business, right at the center of the strategy, heavily based on advanced technologies, coupled with the Brazilian biodiversity, the most biologically diverse in the world, to develop the next generation of therapies. Some of Nintx’s proprietary technologies include xGIbiomics®, which closely emulates the human gastrointestinal digestive system and microbiome, and GAIApath®, an artificial intelligence and analytics solution to map and select medicinal plants with the ability to modulate targets and the microbiome concomitantly. Nintx’s cutting-edge technologies and concepts will be key in the future development of multi-target therapies.